Literature DB >> 12393729

Hepatitic variant of graft-versus-host disease after donor lymphocyte infusion.

Görgün Akpek1, John K Boitnott, Linda A Lee, Jason P Hallick, Michael Torbenson, David A Jacobsohn, Sally Arai, Viki Anders, Georgia B Vogelsang.   

Abstract

Graft-versus-host disease (GVHD) of the liver is characterized by bile duct damage and portal lymphocytic infiltrate. We report acute hepatitislike presentation of GVHD after donor lymphocyte infusion (DLI). Between April 1998 and September 2001, 73 patients received 94 DLI treatments. Liver GVHD developed after DLI in 22 (30%) patients whose median age was 43 years (range, 21 to 61 years). Onset of liver dysfunction was at 35 days (range, 11 to 406 days) after DLI. Fifteen patients underwent liver biopsy, and the diagnosis of liver GVHD was confirmed in 13 (87%) patients. After viral hepatitis and recent drug exposure were excluded, 11 (50%) patients were given a diagnosis of a hepatitic variant of GVHD based on histologic evidence of lobular hepatitis (n = 5), elevation of maximum serum alanine aminotransferase (ALT) or aspartate aminotransferase (AST) level more than 10 times the upper normal limit (n = 9), or both. There was a significant difference in maximum ALT (P =.002) and AST (P =.01) level between the hepatitic-variant and classical GVHD groups. GVHD progressed in 14 (64%) patients, and 10 patients died after a median follow-up of 221 days (range, 31-1284 days). These observations suggest that GVHD that occurs after DLI may have distinct clinical features. Hepatitic-variant GVHD should be considered in the differential diagnosis in DLI recipients with unexplained hepatitis.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12393729     DOI: 10.1182/blood-2002-03-0857

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  21 in total

1.  A flare-up of chronic graft-versus-host disease of the liver that mimics acute hepatitis in a recipient of an allogeneic peripheral blood stem cell transplant.

Authors:  Takehiko Mori; Akihiro Yokoyama; Yoshinobu Aisa; Yasuo Ikeda; Shinichiro Okamoto
Journal:  Int J Hematol       Date:  2005-02       Impact factor: 2.490

2.  A multicentre UK study of GVHD following DLI: rates of GVHD are high but mortality from GVHD is infrequent.

Authors:  J J Scarisbrick; F L Dignan; S Tulpule; E D Gupta; S Kolade; B Shaw; F Evison; G Shah; E Tholouli; G Mufti; A Pagliuca; R Malladi; K Raj
Journal:  Bone Marrow Transplant       Date:  2014-10-13       Impact factor: 5.483

3.  NIH Consensus development project on criteria for clinical trials in chronic graft-versus-host disease: II. The 2014 Pathology Working Group Report.

Authors:  Howard M Shulman; Diana M Cardona; Joel K Greenson; Sangeeta Hingorani; Thomas Horn; Elisabeth Huber; Andreas Kreft; Thomas Longerich; Thomas Morton; David Myerson; Victor G Prieto; Avi Rosenberg; Nathaniel Treister; Kay Washington; Mirjana Ziemer; Steven Z Pavletic; Stephanie J Lee; Mary E D Flowers; Kirk R Schultz; Madan Jagasia; Paul J Martin; Georgia B Vogelsang; David E Kleiner
Journal:  Biol Blood Marrow Transplant       Date:  2015-01-29       Impact factor: 5.742

4.  A proposed biology- and biomarker-based algorithm for management of acute GvHD.

Authors:  A M Ali; J F DiPersio; M A Schroeder
Journal:  Bone Marrow Transplant       Date:  2016-11-21       Impact factor: 5.483

5.  Lenalidomide-induced graft-vs.-Leukemia effect in a patient with chronic lymphocytic leukemia who relapsed after allogeneic stem cell transplant.

Authors:  Rohtesh S Mehta; Antonio Di Stasi; Chitra Hosing; Nina Shah; Katayoun Rezvani; Amin Alousi; Susan O'Brien; William Wierda; Michael Keating; Elizabeth J Shpall
Journal:  Clin Lymphoma Myeloma Leuk       Date:  2013-12-27

6.  Autoimmune-like hepatitis after allogeneic hematopoietic stem cell transplantation: humoral hepatic GvHD.

Authors:  D Koyama; M Ito; E Yokohata; K Watakabe; K Onodera; T Goto; A Seto; K Watanabe; M Doisaki; Y Ozawa; T Yamaguchi; K Miyamura
Journal:  Bone Marrow Transplant       Date:  2016-08-15       Impact factor: 5.483

7.  The treatment of chronic graft-versus-host disease: consensus recommendations of experts from Germany, Austria, and Switzerland.

Authors:  Daniel Wolff; Hartmut Bertz; Hildegard Greinix; Anita Lawitschka; Jörg Halter; Ernst Holler
Journal:  Dtsch Arztebl Int       Date:  2011-10-28       Impact factor: 5.594

8.  How I treat acute graft-versus-host disease of the gastrointestinal tract and the liver.

Authors:  George B McDonald
Journal:  Blood       Date:  2016-01-04       Impact factor: 22.113

9.  National Cancer Institute-National Heart, Lung and Blood Institute/pediatric Blood and Marrow Transplant Consortium First International Consensus Conference on late effects after pediatric hematopoietic cell transplantation: long-term organ damage and dysfunction.

Authors:  Michael L Nieder; George B McDonald; Aiko Kida; Sangeeta Hingorani; Saro H Armenian; Kenneth R Cooke; Michael A Pulsipher; K Scott Baker
Journal:  Biol Blood Marrow Transplant       Date:  2011-10-01       Impact factor: 5.742

10.  Severe hepatocellular injury after hematopoietic cell transplant: incidence, etiology and outcome.

Authors:  M Sakai; S I Strasser; H M Shulman; S J McDonald; H G Schoch; G B McDonald
Journal:  Bone Marrow Transplant       Date:  2009-03-23       Impact factor: 5.483

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.